Across TCGA pan-cancer cohorts, IFNGR1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IFNGR1 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IFNGR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFNGR1 expression acts as an unfavorable survival marker.
UCEC and LUAD are the cancer types where IFNGR1 Mutation most reproducibly stratifies survival.